Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology
— Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals. — Vir Biotechnology's chronic hepatitis delta treatment candidate has shown robust virological responses and reflects a differentiated approach to treatment. Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under […]